{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fmenin-inhibitors-in-aml-UNSQ3it_","width":444,"version":"1.0","type":"rich","title":"A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/5f088726-b190-4db9-a40f-304ca1e92ba4/101166-aml-menin-tm-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/910be8af-a57b-4b54-a9c0-6b6d61e5ed9b\" height=\"200\" width=\"100%\" title=\"A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode, Eytan M. Stein, MD, and Eunice S. Wang, MD, explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care."}